IDYA IDEAYA Biosciences, Inc. Stock Quote

IDYA [NASD]

Index	-	P/E	-	EPS (ttm)	-1.48	Insider Own	6.55%	Shs Outstand	38.59M	Perf Week	10.79%
Market Cap	387.22M	Forward P/E	-	EPS next Y	-2.38	Insider Trans	0.00%	Shs Float	36.12M	Perf Month	-2.35%
Income	-54.80M	PEG	-	EPS next Q	-0.46	Inst Own	94.10%	Short Float	10.46%	Perf Quarter	-28.83%
Sales	32.10M	P/S	12.06	EPS this Y	-1.20%	Inst Trans	5.64%	Short Ratio	9.72	Perf Half Y	-56.65%
Book/sh	7.48	P/B	1.39	EPS next Y	-18.70%	ROA	-14.90%	Target Price	27.75	Perf Year	-46.77%
Cash/sh	6.76	P/C	1.53	EPS next 5Y	-	ROE	-19.10%	52W Range	8.14 - 28.00	Perf YTD	-56.13%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-16.70%	52W High	-62.96%	Beta	-
Dividend %	-	Quick Ratio	4.50	Sales past 5Y	-	Gross Margin	-	52W Low	27.40%	ATR	0.86
Employees	87	Current Ratio	4.50	Sales Q/Q	58.30%	Oper. Margin	-	RSI (14)	50.23	Volatility	9.16% 9.16%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-27.80%	Profit Margin	-	Rel Volume	0.71	Prev Close	11.43
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	388.62K	Price	10.37
Recom	1.60	SMA20	4.32%	SMA50	-5.57%	SMA200	-44.95%	Volume	275,380	Change	-9.27%

Mar-10-22

Upgrade

Stifel

Hold → Buy

$27 → $20

Sep-23-21

Initiated

Stifel

Hold

$27

Jun-04-21

Resumed

Robert W. Baird

Outperform

$28

Mar-11-21

Initiated

Guggenheim

Buy

$32

Oct-07-20

Initiated

Wedbush

Outperform

$21

Sep-01-20

Initiated

Northland Capital

Outperform

$28

Jul-13-20

Upgrade

JP Morgan

Neutral → Overweight

$28

Jun-17-20

Reiterated

H.C. Wainwright

Buy

$13 → $22

Apr-06-20

Initiated

H.C. Wainwright

Buy

$13

Mar-13-20

Initiated

ROTH Capital

Buy

$12

Oct-17-19

Initiated

Oppenheimer

Outperform

$17

Sep-10-19

Initiated

Robert W. Baird

Outperform

Jun-17-19

Initiated

JP Morgan

Neutral

$15

Jun-17-19

Initiated

Jefferies

Buy

$14

Jun-17-19

Initiated

Citigroup

Buy

$20

May-10-22 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Tops Revenue Estimates Zacks +12.56%
06:00AM	IDEAYA Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update PR Newswire
May-06-22 09:59AM	We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate Simply Wall St. -5.30%
May-03-22 06:00AM	IDEAYA Biosciences to Participate in Investor Conferences in May 2022 PR Newswire
May-02-22 06:00AM	IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma PR Newswire
Apr-27-22 05:25PM	Amgen (AMGN) Surpasses Q1 Earnings and Revenue Estimates Zacks
Apr-06-22 06:00AM	IDEAYA Biosciences Appoints Catherine Mackey, Ph.D., to its Board of Directors PR Newswire
Mar-17-22 01:54PM	Bargain Shopping? 2 Strong Buy Stocks That Are Down 50% This Year TipRanks +5.29%
Mar-15-22 08:48AM	Ideaya Biosciences' IDE397 Shows Preliminary Tolerability In Early-Stage Solid Tumor Trial Benzinga
07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Misses Revenue Estimates Zacks
06:00AM	IDEAYA Biosciences, Inc. Reports 2021 Financial Results and Provides Business Update PR Newswire
05:55AM	IDEAYA Biosciences Reports IDE397 Interim Phase 1 Clinical Data PR Newswire
Mar-14-22 06:00AM	IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors PR Newswire
Mar-10-22 05:55PM	Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates Zacks
Mar-08-22 06:00AM	IDEAYA Biosciences Announces Investor Webcast to Report Interim IDE397 Phase 1 Clinical Data and Corporate Update PR Newswire
Mar-01-22 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Lags Revenue Estimates Zacks
06:00AM	IDEAYA Biosciences to Participate in Investor Conferences in March 2022 PR Newswire
Feb-24-22 08:35AM	ProQR (PRQR) Reports Q4 Loss, Misses Revenue Estimates Zacks
Feb-15-22 08:22AM	Cue Biopharma, Inc. (CUE) Stock Jumps 6.5%: Will It Continue to Soar? Zacks
Feb-14-22 09:49AM	IDEAYA Biosciences (NASDAQ:IDYA) investors are sitting on a loss of 20% if they invested a year ago Simply Wall St.
Feb-01-22 06:00AM	IDEAYA Biosciences to Participate in Investor Conferences in February 2022 PR Newswire
Jan-31-22 06:51AM	IDEAYA Advances IDE161 Into IND-Enabling Studies, Exercises Licensing Option For PARG Inhibitors Benzinga +6.63%
06:00AM	IDEAYA Advances First-in-Class PARG Development Candidate, IDE161, into IND-Enabling Studies and Exercises Option with Cancer Research UK and University of Manchester for Exclusive Worldwide License PR Newswire
Jan-10-22 06:00AM	IDEAYA Biosciences Announces Corporate and Portfolio Update for J.P. Morgan 40th Annual Healthcare Conference PR Newswire
Jan-05-22 06:00AM	IDEAYA Biosciences Announces Acquisition of Proprietary INQUIRE Chemical Library to Enhance Synthetic Lethality Drug Discovery Platform PR Newswire -9.37%
Jan-04-22 06:00AM	IDEAYA Biosciences Appoints Dr. Frank McCormick as Chair of Scientific Advisory Board PR Newswire -7.12%
Jan-03-22 06:00AM	IDEAYA Biosciences to Participate in Investor Conferences in January 2022 PR Newswire
Dec-21-21 01:38AM	Federated Hermes Kaufmann Fund II Buys GXO Logistics Inc, Seres Therapeutics Inc, Domo Inc, ... GuruFocus.com
Dec-07-21 07:00AM	IDEAYA Reports Clinical Data from Phase 2 Expansion Dose of Darovasertib and Crizotinib Synthetic Lethal Combination in Heavily Pre-Treated Metastatic Uveal Melanoma PR Newswire +7.59%
Nov-30-21 06:00AM	IDEAYA Biosciences to Participate in Investor Conferences in December 2021 PR Newswire
Nov-29-21 06:00AM	IDEAYA Announces Investor Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib Combination with Crizotinib in Metastatic Uveal Melanoma PR Newswire -6.22%
Nov-15-21 08:44AM	What Kind Of Shareholders Hold The Majority In IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) Shares? Simply Wall St.
06:01AM	IDEAYA Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update PR Newswire
Nov-04-21 03:01PM	Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline Zacks
Nov-01-21 06:00AM	IDEAYA Biosciences to Participate in Investor Conferences in November 2021 PR Newswire
Oct-18-21 06:00AM	IDEAYA Biosciences Appoints Michael White, Ph.D., as Chief Scientific Officer PR Newswire
Sep-10-21 04:57PM	SVP And Chief Scientific Officer Of Ideaya Biosciences Trades $394.04 Thousand In Company Stock Benzinga
Aug-30-21 06:00AM	IDEAYA Biosciences to Participate in Investor Conferences in September 2021 PR Newswire
Aug-16-21 08:26AM	Investors in IDEAYA Biosciences (NASDAQ:IDYA) have made a decent return of 99% over the past year Simply Wall St.
Aug-10-21 07:15AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates Zacks
06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update PR Newswire
Aug-02-21 06:00AM	IDEAYA Biosciences to Participate in Panel Discussion at 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021 PR Newswire
Jul-12-21 04:11PM	IDEAYA Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire +6.53%
Jul-08-21 06:39AM	IDEAYA Prices 4.6M Common Stock Offering; Street Says Buy SmarterAnalyst
Jul-07-21 09:29PM	IDEAYA Announces Pricing of Public Offering of Common Stock PR Newswire -20.29%
08:01AM	Ideaya Biosciences Launches Equity Offering Of $80M Benzinga
Jul-06-21 04:01PM	IDEAYA Announces Proposed Public Offering of Common Stock PR Newswire
Jun-28-21 06:00AM	IDEAYA Announces IDE397 Phase 1 Clinical Pharmacodynamic Data and Phase 2 Initiation of Darovasertib and Crizotinib Combination PR Newswire
May-24-21 06:01AM	IDEAYA Biosciences to Present at 2021 Jefferies Virtual Healthcare Conference PR Newswire
May-16-21 05:21AM	How Many IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Do Institutions Own? Simply Wall St.
May-10-21 07:30AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q1 Loss, Misses Revenue Estimates Zacks
06:00AM	IDEAYA Biosciences, Inc. Reports First Quarter 2021 Financial Results and Provides Business Update PR Newswire
06:00AM	IDEAYA Announces Dose Expansion in Phase 1/2 Study of Darovasertib and Crizotinib Combination based on Early Clinical Efficacy in First Combination Cohort PR Newswire
May-06-21 06:00AM	IDEAYA to Participate in Upcoming May 2021 Investor Relations Event PR Newswire
Apr-19-21 06:00AM	IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 PR Newswire
Apr-18-21 08:30AM	2 Biotech Start-Ups Are Searching for Cancers Hidden Weaknesses. What to Know. Barrons.com
Apr-16-21 06:00AM	IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma PR Newswire
Apr-15-21 04:01PM	IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma PR Newswire
06:00AM	IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors PR Newswire
Mar-23-21 10:24AM	IDEAYA Posts Better-Than-Feared Quarterly Loss, Sales Top Estimates SmarterAnalyst
07:30AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Lags Revenue Estimates Zacks
06:05AM	IDEAYA Biosciences, Inc. Reports Fourth Quarter 2020 Financial Results and Provides Business Update PR Newswire
06:05AM	IDEAYA Announces Dose Expansion in Phase 1/2 Study of IDE196 and Binimetinib Combination in Metastatic Uveal Melanoma Based on Early Clinical Activity PR Newswire
Mar-11-21 06:00AM	IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196 PR Newswire +5.25%
Mar-01-21 06:00AM	IDEAYA to Participate in Upcoming March 2021 Investor Relations Events PR Newswire
Feb-22-21 06:00AM	IDEAYA Biosciences Announces Inaugural Synthetic Lethality Investor Day PR Newswire
Feb-17-21 06:00AM	IDEAYA Biosciences Appoints Susan L. Kelley, M.D., an Industry Veteran in Medical Oncology and Clinical Development, to its Board of Directors PR Newswire
Feb-15-21 01:12AM	Announcing: IDEAYA Biosciences (NASDAQ:IDYA) Stock Increased An Energizing 178% In The Last Year Simply Wall St.
Feb-08-21 06:00AM	IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical Affairs PR Newswire +8.83%
Feb-01-21 06:00AM	IDEAYA to Participate in Upcoming February 2021 Investor Relations Events PR Newswire
Jan-19-21 06:00AM	Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry PR Newswire +15.37%
Jan-11-21 06:00AM	IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA PR Newswire +6.65%
Jan-05-21 06:00AM	IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor PR Newswire
Jan-04-21 06:00AM	IDEAYA to Participate in Upcoming January 2021 Investor Relations Events and Scientific Conferences PR Newswire
Dec-14-20 06:00AM	IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index PR Newswire
Dec-11-20 10:23PM	Is IDYA A Good Stock To Buy Now? Insider Monkey -13.17%
Dec-08-20 12:43PM	IDEAYA Biosciences (IDYA) Jumps: Stock Rises 8.2% Zacks
Nov-16-20 11:19PM	Industry Analysts Just Upgraded Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts By 95% Simply Wall St.
Nov-15-20 08:50AM	Results: IDEAYA Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts Simply Wall St.
Nov-12-20 06:00AM	IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update PR Newswire
Nov-02-20 06:00AM	IDEAYA to Participate in Upcoming November 2020 Investor Relations Events PR Newswire
Oct-22-20 06:00AM	IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform PR Newswire +5.53%
Sep-24-20 08:15AM	The Daily Biotech Pulse: Gilead's $7.25B Debt Offering, Lexicon Deleverages, Taysha Gene Therapies Prices IPO Benzinga
06:00AM	IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreement to Evaluate Clinical Combination of IDE196 and Crizotinib in Solid Tumors Harboring GNAQ or GNA11 Mutations PR Newswire
Sep-04-20 12:52PM	Billionaire Ken Griffin Snaps Up These 3 Strong Buy Stocks TipRanks
Sep-02-20 06:21PM	LD Micro 360 Companies --Set to Present this Week. ACCESSWIRE +7.38%
Aug-31-20 06:00AM	IDEAYA to Participate in Upcoming September 2020 Investor Relations Events PR Newswire
Aug-19-20 01:33PM	What Kind Of Shareholders Hold The Majority In IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) Shares? Simply Wall St.
Aug-12-20 07:30AM	IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates Zacks
06:00AM	IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update PR Newswire
Aug-07-20 08:33AM	Is a Surprise Coming for IDEAYA Biosciences (IDYA) This Earnings Season? Zacks +6.11%
Aug-05-20 04:21PM	LD Micro--Announces Preliminary List of Presenters for the LD-500. ACCESSWIRE
Aug-04-20 06:00AM	IDEAYA Announces HSR Clearance of GSK Strategic Partnership in Synthetic Lethality and Closing of Glaxo Group Equity Investment PR Newswire
Jul-16-20 06:00AM	IDEAYA Announces IDE196 Program Update and Clinical Protocol Criteria Met for Cohort Expansion in Skin Melanoma for Phase 2 GNAQ/11 Basket Trial PR Newswire
Jul-14-20 06:00AM	IDEAYA to Participate in Fireside Chat at BTIG Biotechnology Conference and Wedbush PacGrow Healthcare Conference on August 11 and 12, 2020 PR Newswire -5.72%
Jul-09-20 06:00AM	IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Binimetinib, a MEK Inhibitor PR Newswire
Jun-30-20 06:00AM	IDEAYA Appoints Garret Hampton, Ph.D., to the Board of Directors, an Industry Leader in Precision Medicine Oncology and Diagnostics PR Newswire +7.25%
Jun-22-20 04:35PM	Repare and Forma Shares Gobbled Up in IPO GuruFocus.com
Jun-17-20 09:34PM	IDEAYA Announces Pricing of Public Offering of Common Stock PR Newswire +44.63%
09:53AM	Biotech Stock Roundup: REGN Begins Coronavirus Study, VRTX, BIIB Give Updates Zacks

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate is IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting IDE397, a methionine adenosyltransferase 2a inhibitor for patients with solid tumors having MTAP deletions; PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in high microsatellite instability tumors. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dillon Michael P.	SVP, Chief Scientific Officer	Oct 04	Option Exercise	11.08	1,500	16,620	80,289	Oct 07 04:11 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Oct 04	Sale	26.36	1,500	39,545	78,789	Oct 07 04:11 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Sep 08	Option Exercise	6.87	11,384	78,264	90,173	Sep 09 07:24 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Sep 08	Sale	27.42	11,384	312,093	78,789	Sep 09 07:24 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Sep 07	Option Exercise	4.31	116	500	78,905	Sep 09 07:24 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Sep 07	Sale	27.46	116	3,185	78,789	Sep 09 07:24 PM
Stone Paul A.	SVP, Chief Financial Officer	Sep 07	Sale	27.42	2,500	68,542	12,944	Sep 09 05:41 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Sep 02	Sale	25.09	10,000	250,943	78,789	Sep 07 06:48 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Aug 09	Option Exercise	4.31	1,500	6,465	100,289	Aug 11 05:19 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Aug 09	Sale	22.98	11,500	264,269	88,789	Aug 11 05:19 PM
Throne Jason	SVP, General Counsel	Jul 27	Option Exercise	13.34	10,000	133,400	10,000	Jul 29 05:17 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jul 27	Option Exercise	5.62	10,000	56,150	108,789	Jul 29 05:18 PM
Throne Jason	SVP, General Counsel	Jul 27	Sale	25.17	10,000	251,683	0	Jul 29 05:17 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jul 27	Sale	25.15	10,000	251,460	98,789	Jul 29 05:18 PM
Throne Jason	SVP, General Counsel	Jul 06	Option Exercise	8.52	10,000	85,229	10,000	Jul 08 07:00 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jul 06	Option Exercise	6.92	1,500	10,380	100,289	Jul 08 07:01 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jul 06	Sale	22.24	1,500	33,358	98,789	Jul 08 07:01 PM
Throne Jason	SVP, General Counsel	Jul 06	Sale	22.24	10,000	222,408	0	Jul 08 07:00 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jun 17	Option Exercise	6.92	3,893	26,940	102,682	Jun 17 08:59 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jun 17	Sale	22.49	3,893	87,540	98,789	Jun 17 08:59 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jun 16	Option Exercise	6.92	1,107	7,660	99,896	Jun 17 08:59 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jun 16	Sale	22.47	1,107	24,873	98,789	Jun 17 08:59 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jun 07	Option Exercise	6.92	1,500	10,380	100,289	Jun 09 06:12 PM
Dillon Michael P.	SVP, Chief Scientific Officer	Jun 07	Sale	20.22	1,500	30,333	98,789	Jun 09 06:12 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience